🔒 Read-only preview. Create a free account to simulate your own scenarios, save them, compare side-by-side, and export to PDF.

FREE TOOL · PHARMA

Patient Support Program (PSP) ROI Calculator

Model the economic case for a structured PSP — PNA reduction, 12-month persistence uplift, switch-away avoided, and downstream clinical savings where evidence supports it. Spain peer-reviewed anchors (Márquez-Contreras 2011, Cramer 2008, Simoni-Wastila 2012). Compliant framing for Farmaindustria + AEMPS SVAM guidance.

Therapy class

Therapy class drives every baseline (PNA, persistence, switch, revenue/patient, PSP cost). Pick yours first — the rest auto-fills from Spain literature anchors.

Cohort + revenue

Patient cohort eligibles / year

Patients eligible for the PSP per year. For a brand-specific case, use your real Spain/EU estimate.

Annual treatment revenue per patient

Spain/EU post-discount median annual revenue for this therapy class.

€

Baselines (current state)

Baseline PNA (Primary Non-Adherence) %

Patients who never fill the initial Rx. Spain HTA: 12-15% (Márquez-Contreras 2011). Specialty injectables higher (~28%).

5% – 35%13%

Baseline 12-month persistence %

% of starting patients still on therapy at month 12. EU/Spain median by class (Cramer 2008 cardiometabolic; Hengerer 2017 biologics).

25% – 85%50%

Baseline annual switch-away rate %

Patients/year who switch to a competing brand within the same class. IQVIA EU benchmarks: 5-15% by class.

3% – 25%10%

Baseline copay / savings program uptake %

% of eligibles enrolled in your copay/savings program. EU/Spain industry: 30-70%.

20% – 80%50%

PSP integration + cost

PSP integration level

Drives the modeled uplift on PNA, persistence, copay uptake, and switch-away. Advanced = Serena value prop (AI-structured nurse-escalation).

Modeled uplift: -10% relative PNA, +5pp 12-month persistence, +5pp copay uptake, -5% relative switch-away.

PSP cost per enrolled patient / year

Auto-fills from the chosen therapy class + integration level. Adjust to your contracted vendor cost.

€

PSP ROI multiplier

0.82×

Revenue retained ÷ PSP cost. >3× = strong case for advanced PSP. 1-3× = defensible but tight; <1× = the program loses money before downstream clinical savings.

Revenue retained (annual)

€1.453.639

2208 additional patient-years × your revenue per patient.

PSP cost (annual)

€1.766.000

Enrolled cohort × per-patient/year program cost at the chosen integration level.

Additional patient-years

+2208

Total patient-time on therapy gained from the persistence uplift. Each patient-year ≈ one full year of patient-on-therapy at your revenue per patient.

Additional Rx fills (PNA reduction)

+650

Patients who now fill their initial prescription thanks to the PSP's PNA recovery. These convert directly into revenue if they persist.

Switch-away avoided

+221

Patients/year retained on this brand instead of switching to a competing brand within the same class.

LTV per enrolled patient

€507

3-year geometric projection — revenue per patient × cumulative persistence at the optimized level. Excludes downstream clinical savings.

Cohort survival curve — 24 months

ROI breakdown

Compliance · Farmaindustria · RGPD

This simulator does not constitute medical advice and is not a tool for promotional claims. PSP outcomes vary by therapy class, patient population, and program design — real-world results require validation against your specific cohort. Compliance with Código de Farmaindustria, RGPD, and AEMPS guidance on Servicios de Valor Añadido al Medicamento (SVAM) is the responsibility of the implementing organization.

Export PDF

Keep going

Model your own PSP scenario in under a minute.

Free account. No card required. Save scenarios, compare 2-4 side by side, export PDF for your team. Calibrated for Spain/EU pharma (Márquez-Contreras, Cramer, Simoni-Wastila, Hengerer).

Create free account →